Guo Jing, Cao Yi, Wu Qing-Yuan, Cen Lu-Sha
Department of Dermatology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang Province, China.
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China.
World J Diabetes. 2024 Oct 15;15(10):2002-2005. doi: 10.4239/wjd.v15.i10.2002.
Diabetic cardiomyopathy (DCM), a complication of diabetes, poses a significant threat to public health, both its diagnosis and treatment presents challenges. Teneligliptin has promising applications and research implications in the treatment of diabetes mellitus. Zhang observed the therapeutic effect of teneligliptin on cardiac function in mice with DCM. They validated that teneligliptin's mechanism of action in treating DCM involves cardiomyocyte protection and inhibition of inflammasome activity. Given that the inflammasome plays a crucial role in the onset and progression of DCM, it presents a promising therapeutic target. Nevertheless, further clinical validation is required to ascertain the preventive and therapeutic efficacy of teneligliptin in DCM.
糖尿病性心肌病（DCM）是糖尿病的一种并发症，对公众健康构成重大威胁，其诊断和治疗均面临挑战。替格列汀在糖尿病治疗中具有广阔的应用前景和研究意义。张等人观察了替格列汀对DCM小鼠心脏功能的治疗效果。他们证实，替格列汀治疗DCM的作用机制包括心肌细胞保护和炎性小体活性抑制。鉴于炎性小体在DCM的发生和发展中起关键作用，它是一个有前景的治疗靶点。然而，需要进一步的临床验证来确定替格列汀在DCM中的预防和治疗效果。
